ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ZVSA ZyVersa Therapeutics Inc

0.60
-0.026 (-4.15%)
20 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
ZyVersa Therapeutics Inc ZVSA NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.026 -4.15% 0.60 09:59:30
Open Price Low Price High Price Close Price Previous Close
0.64 0.571 0.64 0.586 0.626
more quote information »

Recent News

Date Time Source Heading
04/4/202422:57GLOBEZyVersa Therapeutics Highlights Published Data Demonstrating..
25/3/202423:17GLOBEZyVersa Therapeutics Reports Full Year 2023 Financial..
18/3/202422:57GLOBEZyVersa Therapeutics Announces IRB Approval of Phase 2a..
14/3/202422:57GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover to Participate..
09/3/202409:00EDGAR2Form 8-K - Current report
09/3/202409:00EDGAR2Form PRE 14A - Other preliminary proxy statements
29/2/202423:57GLOBEZyVersa Therapeutics Generated Approximately $2.7 Million..
28/2/202423:57GLOBEZyVersa Therapeutics Highlights Data from Review Article..
22/2/202423:47GLOBEZyVersa Therapeutics Publishes New White Paper Detailing the..
15/2/202408:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/2/202423:53GLOBEZyVersa Therapeutics Highlights Review Article..
08/2/202400:02GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover to Present at..
31/1/202423:57GLOBEZyVersa Therapeutics Highlights Publication Indicating That..
24/1/202423:57GLOBEZyVersa Therapeutics Announces Peer-Reviewed Article..
19/1/202422:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
17/1/202423:52GLOBEZyVersa Therapeutics Highlights Peer-Reviewed Article..
11/1/202400:06GLOBEZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on..
04/1/202423:50GLOBEZyVersa Therapeutics Announces Equity Research Coverage..
04/1/202400:07GLOBEZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter..
23/12/202308:45EDGAR2Form 8-K - Current report
19/12/202300:12GLOBEZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate..
14/12/202323:01GLOBEZyVersa Therapeutics Engages CRO, George Clinical, for Phase..
12/12/202308:30EDGAR2Form 8-K - Current report
09/12/202308:44EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
08/12/202303:20GLOBEZyVersa Therapeutics Announces Publication Demonstrating..
07/12/202316:15EDGAR2Form EFFECT - Notice of Effectiveness
07/12/202313:00GLOBEZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million..
06/12/202323:20GLOBEZyVersa Therapeutics Announces Publication Showing AIM2 and..
01/12/202303:45EDGAR2Form 8-K - Current report
01/12/202303:30GLOBEZyVersa Therapeutics, Inc. Announces Reverse Stock Split and..
21/11/202309:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/11/202308:15EDGAR2Form 8-K - Current report
15/11/202308:35GLOBEZyVersa Therapeutics Reports Third Quarter 2023 Corporate..
09/11/202323:35GLOBEZyVersa Therapeutics Announces Article Published in..
06/11/202323:05GLOBEZyVersa Therapeutics Announces Article in Peer-Reviewed..
03/11/202307:37EDGAR2Form 8-K - Current report
01/11/202323:07GLOBEZyVersa Therapeutics Announces Publication in Molecular..
25/10/202321:50GLOBEZyVersa Therapeutics Announces Research Published in the..
25/10/202307:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/10/202322:05GLOBEZyVersa Therapeutics Announces a Publication in the..
18/10/202307:15EDGAR2Form S-1/A - General form for registration of securities..
11/10/202322:05GLOBEZyVersa Therapeutics Announces Peer-Reviewed Publication in..
04/10/202322:05GLOBEZyVersa Therapeutics Announces New Peer-Reviewed Publication..
27/9/202321:07GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover to Participate..
22/9/202320:35GLOBEZyVersa Therapeutics Announces Research Published in The..
21/9/202307:15EDGAR2Form 8-K/A - Current report: [Amend]
14/9/202321:00EDGAR2Form 8-K - Current report
14/9/202306:57EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
14/9/202306:40EDGAR2Form DEF 14A - Other definitive proxy statements
12/9/202320:30GLOBEZyVersa Therapeutics Announces Research Published in..

Your Recent History

Delayed Upgrade Clock